$RCUS
Arcus Biosciences, Inc.

2018 Q4 Form 10-Q Financial Statement

#000156459018028583 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $1.562M $4.291M $163.0K
YoY Change 24.96% 2532.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.610M $3.580M $1.860M
YoY Change 47.35% 92.47%
% of Gross Profit
Research & Development $11.44M $12.86M $21.44M
YoY Change -5.84% -40.01%
% of Gross Profit
Depreciation & Amortization $1.000M $900.0K $700.0K
YoY Change 25.0% 28.57%
% of Gross Profit
Operating Expenses $15.05M $16.44M $23.30M
YoY Change 3.1% -29.45%
Operating Profit -$12.15M -$23.13M
YoY Change -47.5%
Interest Expense $1.190M $1.330M $10.00K
YoY Change 815.38% 13200.0%
% of Operating Profit
Other Income/Expense, Net $1.333M $12.00K
YoY Change 11008.33%
Pretax Income -$12.30M -$10.81M -$23.12M
YoY Change -6.89% -53.24%
Income Tax
% Of Pretax Income
Net Earnings -$12.30M -$10.81M -$23.12M
YoY Change -6.93% -53.24%
Net Earnings / Revenue -787.13% -251.97% -14185.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.235M -$252.3K -$555.1K
COMMON SHARES
Basic Shares Outstanding 44.45M 44.45M 3.995M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.5M $257.8M
YoY Change
Cash & Equivalents $71.06M $74.89M $18.31M
Short-Term Investments $185.5M $182.9M
Other Short-Term Assets $2.300M $2.300M
YoY Change
Inventory
Prepaid Expenses
Receivables $5.000M
Other Receivables $100.0K
Total Short-Term Assets $258.9M $265.3M
YoY Change 46.41%
LONG-TERM ASSETS
Property, Plant & Equipment $11.11M $11.76M
YoY Change -1.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.202M $1.525M
YoY Change 76.25%
Other Assets $284.0K $205.0K
YoY Change -81.09%
Total Long-Term Assets $15.98M $21.44M
YoY Change 17.33%
TOTAL ASSETS
Total Short-Term Assets $258.9M $265.3M
Total Long-Term Assets $15.98M $21.44M
Total Assets $274.9M $286.7M
YoY Change 44.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.102M $2.109M
YoY Change -18.8%
Accrued Expenses $6.023M $6.667M
YoY Change 92.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.94M $16.61M
YoY Change 33.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.792M $2.047M
YoY Change 217.17%
Total Long-Term Liabilities $1.792M $2.047M
YoY Change 217.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.94M $16.61M
Total Long-Term Liabilities $1.792M $2.047M
Total Liabilities $39.98M $41.60M
YoY Change 9.19%
SHAREHOLDERS EQUITY
Retained Earnings -$122.8M -$110.5M
YoY Change 67.72%
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $234.9M $245.1M
YoY Change
Total Liabilities & Shareholders Equity $274.9M $286.7M
YoY Change 44.33%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$12.30M -$10.81M -$23.12M
YoY Change -6.93% -53.24%
Depreciation, Depletion And Amortization $1.000M $900.0K $700.0K
YoY Change 25.0% 28.57%
Cash From Operating Activities -$7.100M -$11.80M -$24.20M
YoY Change -145.81% -51.24%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$1.100M -$800.0K
YoY Change -33.33% 37.5%
Acquisitions
YoY Change
Other Investing Activities $2.800M -$82.20M $13.60M
YoY Change -106.7% -704.41%
Cash From Investing Activities $2.600M -$83.40M $12.70M
YoY Change -106.18% -756.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 800.0K 0.000 200.0K
YoY Change -99.25% -100.0%
NET CHANGE
Cash From Operating Activities -7.100M -11.80M -24.20M
Cash From Investing Activities 2.600M -83.40M 12.70M
Cash From Financing Activities 800.0K 0.000 200.0K
Net Change In Cash -3.700M -95.20M -11.30M
YoY Change -104.63% 742.48%
FREE CASH FLOW
Cash From Operating Activities -$7.100M -$11.80M -$24.20M
Capital Expenditures -$200.0K -$1.100M -$800.0K
Free Cash Flow -$6.900M -$10.70M -$23.40M
YoY Change -143.67% -54.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44453724
CY2018Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
5000000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74889000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98426000
CY2018Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
182948000
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
77277000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2329000
CY2018Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
114000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
265280000
CY2018Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
7746000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11762000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11230000
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-260000
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1699045
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-23122000
us-gaap Net Income Loss
NetIncomeLoss
-37299000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-25000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
153993227
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44453724
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4090898
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44453724
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4090898
CY2018Q3 us-gaap Revenues
Revenues
4291000
CY2017Q3 us-gaap Revenues
Revenues
163000
us-gaap Revenues
Revenues
6791000
us-gaap Revenues
Revenues
163000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017Q4 us-gaap Equity Method Investments
EquityMethodInvestments
682000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
205000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1502000
CY2018Q3 us-gaap Assets
Assets
286721000
CY2017Q4 us-gaap Assets
Assets
190486000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2109000
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1585000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
769000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16611000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12726000
CY2018Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
18546000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
18587000
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4396000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4740000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2047000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
565000
CY2018Q3 us-gaap Liabilities
Liabilities
41600000
CY2017Q4 us-gaap Liabilities
Liabilities
36618000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355758000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110533000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-108000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
245121000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
286721000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1141000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
611000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
33000
us-gaap Net Income Loss
NetIncomeLoss
-39872000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1862000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9956000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5188000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
16436000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
23297000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23134000
us-gaap Operating Expenses
OperatingExpenses
48166000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12145000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35072000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-66000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23108000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37365000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39855000
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.25
CY2017Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-11.86
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.16
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42838098
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1949258
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
25000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
176869000
CY2018Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1525000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3820000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3137000
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6250000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000000
CY2018Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
226196000
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
948000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73234000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-42000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-72328000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
190486000
CY2018Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
120958867
CY2018Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
30459574
CY2018Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
30459574
CY2017Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
226725
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1333000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4076000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
225000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-10812000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
14000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10837000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-23.47
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32056675
us-gaap Profit Loss
ProfitLoss
-37299000
us-gaap Profit Loss
ProfitLoss
-39872000
us-gaap Share Based Compensation
ShareBasedCompensation
2820000
us-gaap Share Based Compensation
ShareBasedCompensation
340000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2717000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1846000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-563000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
1229000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1017000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-82000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
177000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
76000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
5000000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
25000000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
89000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-370000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1188000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12859000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21435000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38210000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3577000
us-gaap Operating Expenses
OperatingExpenses
40260000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41375000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40097000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5220000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
28000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1209000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
24837000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1288000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1029000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2306000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4141000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40646000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
222067000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
37718000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
109601000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
35933000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3485000
rcus Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-344000
rcus Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-478000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35889000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-115951000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7005000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
125111000
rcus Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchases
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchases
3327000
rcus Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchases
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchases
797000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
135000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
128303000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
797000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23537000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46854000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65160000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18306000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
33000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
103000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000
rcus Vesting Of Early Exercised Stock Options And Restricted Stock
VestingOfEarlyExercisedStockOptionsAndRestrictedStock
982000
rcus Vesting Of Early Exercised Stock Options And Restricted Stock
VestingOfEarlyExercisedStockOptionsAndRestrictedStock
140000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note </font><font style="color:#000000;">1. </font>Organization</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences, Inc. (Company or the Company) is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, the Company targets well-characterized biological pathways with significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, the Company has built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates. Since its inception in 2015, the Company has built a broad portfolio of small molecule and antibody product candidates that it plans to develop together as intra-portfolio combinations. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 21, 2018, the Company completed its initial public offering (IPO) pursuant to which the Company issued 9,200,000 shares of common stock, including the exercise of the underwriters&#8217; overallotment option to purchase 1,200,000 shares of common stock, at an offering price at $15.00 per share. The Company received aggregate net proceeds of approximately $124.7 million after deducting underwriting discounts and other offering related costs. In addition, in connection with the completion of the Company&#8217;s IPO, all outstanding shares of convertible preferred stock were converted into 30,459,574 shares of common stock and the Company amended and restated its certificate of incorporation and bylaws, which, among other things, changed the authorized capital stock to 400,000,000 shares of common stock and 10,000,000 shares of preferred stock, each with a par value of $0.0001 per share. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2018, the Company had cash and investments of $265.6 million, of which $257.8 million are cash, cash equivalents, and short-term investments which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this report.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosure of contingent assets and liabilities. Estimates were used to determine the fair value of common stock prior to the IPO and are used to determine stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company&#8217;s estimates. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk.&nbsp;&nbsp;The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes.&nbsp;&nbsp;The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. </p></div>
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Investments And Cash
InvestmentsAndCash
265600000
rcus Description To Be Remained In Emerging Growth Company
DescriptionToBeRemainedInEmergingGrowthCompany
The Company will remain an emerging growth company until the earliest of (1) the last day of its first fiscal year (a) following the fifth anniversary of the completion of its initial public offering, (b) in which the Company has a total annual gross revenue of at least $1.07 billion, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of the common stock that is held by non-affiliates exceeds $700.0 million of the prior June 30th and (2) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
rcus Minimum Annual Gross Revenue To Remain Classified As Emerging Growth Company
MinimumAnnualGrossRevenueToRemainClassifiedAsEmergingGrowthCompany
1070000000
CY2017Q2 rcus Minimum Market Value Of Common Stock Held By Non Affiliates To Be Remained In Emerging Growth Company
MinimumMarketValueOfCommonStockHeldByNonAffiliatesToBeRemainedInEmergingGrowthCompany
700000000
CY2018Q3 rcus Additional Non Convertible Debt Securities To Be Remained In Emerging Growth Company
AdditionalNonConvertibleDebtSecuritiesToBeRemainedInEmergingGrowthCompany
1000000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
the Company effected a reverse split of all shares of its common and preferred stock at a ratio of 1-for-3.96
CY2018Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2525
CY2018Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3600000
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1300000
CY2018Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
74889000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
98426000
CY2018Q3 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
265583000
CY2017Q4 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
175703000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2017 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
340000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
130000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
175745000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
175703000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1048000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
136000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1526989
CY2018Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2820000
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
713931
CY2017Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
113867
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
632926
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18458000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15208000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6696000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3816784
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
212000
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44452184
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3994915
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
147955
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1014537
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.45
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.74
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33937800
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3978000
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2700000
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1800000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2761000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1026000
CY2018Q3 rcus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3604000
CY2017Q4 rcus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1193000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
116000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
706000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000
CY2018Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1614086
CY2017Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2045657
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1881125
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2117739
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.86
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.47
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2862021
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23859782

Files In Submission

Name View Source Status
0001564590-18-028583-index-headers.html Edgar Link pending
0001564590-18-028583-index.html Edgar Link pending
0001564590-18-028583.txt Edgar Link pending
0001564590-18-028583-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcus-10q_20180930.htm Edgar Link pending
rcus-20180930.xml Edgar Link completed
rcus-20180930.xsd Edgar Link pending
rcus-20180930_cal.xml Edgar Link unprocessable
rcus-20180930_def.xml Edgar Link unprocessable
rcus-20180930_lab.xml Edgar Link unprocessable
rcus-20180930_pre.xml Edgar Link unprocessable
rcus-ex101_134.htm Edgar Link pending
rcus-ex102_135.htm Edgar Link pending
rcus-ex311_9.htm Edgar Link pending
rcus-ex312_7.htm Edgar Link pending
rcus-ex321_6.htm Edgar Link pending
rcus-ex322_8.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending